GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Net Income (Continuing Operations)

Noxopharm (ASX:NOX) Net Income (Continuing Operations) : A$-12.13 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Noxopharm's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was A$-2.50 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-12.13 Mil.

Noxopharm Net Income (Continuing Operations) Historical Data

The historical data trend for Noxopharm's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Net Income (Continuing Operations) Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Continuing Operations)
Get a 7-Day Free Trial -12.57 -1.00 -9.35 -18.67 -15.06

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.61 -10.05 -5.43 -9.63 -2.50

Noxopharm Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noxopharm  (ASX:NOX) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Noxopharm Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Noxopharm's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Net Income (Continuing Operations)
Comparable Companies
ASX:AGN ASX:BIO ASX:RAD ASX:EZZ ASX:PAA ASX:CYP ASX:ACW ASX:1AI ASX:VBS ASX:KZA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NOXOF:USA
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Website
https://www.noxopharm.com
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines